CYR61 down-modulation sensitizes prostate cancer cells to zoledronic acid and docetaxel: A new anti-cancer strategy  by Caraglia, M. et al.
Abstracts
Genitourinary cancer
SUNITINIB IN ADVANCED CLEAR CELL RENAL CANCER: A
SINGLE CENTRE EXPERIENCE
G.S. Bruni, G. Facchini, V.R. Iaffaioli, C. Pisano, S. Pignata. Uro-
Gynecologic Department, National Cancer Institute of Naples, Italy
Renal cell carcinoma represents 2–3% of all cancer. New sys-
temic therapies have reached the market in the last 2 years. Sun-
itinib was found to be superior to IFN-a in a phase III trial in
metastatic renal cancer patients (mRC). Fatigue, gastrointestinal
and skin are the most frequently reported toxicities. Most of them
are easily solved with medical intervention or dose changes. In our
center we evaluated the sunitinib compliance and activity in an
unselected series of consecutive patients. In the first year after
sunitinib availability in Italy, 17 consecutive patients (13 male, 4
female, median age 62 years, range 40–81) with intermediate/poor
risk mRC were treated in our institution. Most frequent metastatic
sites were lung, pleura, bone, nodes and liver. Six out of 17 patients
were pretreated with cytokines. Overall 68 cycles of sunitinib were
given (range 1–11). Objective responses were observed in 5
patients (29%), while stable disease was observed in 4 patients
(23%) (overall clinical benefit 52%). Toxicity was as follows:
Results: Dose reductions were done in 9/17 patients (skin 1,
mucositis 4, hearth 2, fatigue 1, anemia 1), and in 3 cases treatment
was temporaneously interrupted due to toxicity. In conclusions,
sunitinib was confirmed to have significant activity in mRC. G3 tox-
icities are unfrequent, but often require dose modifications. Self-
training and internal guidelines in side effects medical treatment
and dose reduction rules seems crucial for an optimal use of suni-
tinib in unselected patients out of clinical trials.
doi:10.1016/j.ejcsup.2008.06.046
CYR61 DOWN-MODULATION SENSITIZES PROSTATE CANCER
CELLS TO ZOLEDRONIC ACID AND DOCETAXEL: A NEW ANTI-
CANCER STRATEGY
M. Caraglia a, M. Marra a, G. Meo a, S. Zappavigna a, B. Vincenzi b,
A. Baldi c, M. Rosolowski d, M. Loeffler d, G. Tonini b, D. Santini b, A.
Budillon a. aDepartment of Research, Experimental Pharmacology Unit,
National Institute of Tumours Pascale, Naples, Italy. bMedical Oncology,
University Campus Bio-Medico, Rome, Italy. cSecond University of
Naples, Italy. d Institute for Medical Informatics, Statistics and
Epidemiology, University of Leipzig, Germany
We have analysed the gene modulation induced by zoledronic
acid (ZOL) in androgen-resistant prostate cancer PC3 cells with
cDNA microarray platform to identify new molecular targets of
ZOL in prostate cancer. The gene coding for cysteine-rich, angio-
genic inducer, 61 (CYR61), often over-expressed in tumour cells,
resulted highly down-regulated with a fold-change of 5.58. There-
fore, we have studied the effects of different concentrations of
ZOL on CYR61 protein product and we have found that CYR61
protein expression was significantly decreased after exposure to
ZOL. The effect of ZOL on CYR61 expression was dose and time-
dependent and was due to a reduced transcriptional activity of
CYR61 promoter as demonstrated by transfection with a plasmid
encoding for luc-CYR61 promoter. Interestingly, other signal
transduction inhibitors or cytotoxic agents did not induce or
induced less effect on CYR61 modulation if compared to ZOL.
Moreover, ZOL reduced CYR61 expression through decreased acti-
vation of ras-raf-1-dependent pathway that was dependent from
isoprenylation inhibition since they were antagonized by the
addition of either farnesol or geranilgeraniol. Finally, we have
investigated the role of CYR61 in the regulation of growth inhibi-
tion and invasion/motility of PC3 cells using a shRNA for CYR61 in
order to down-regulate the expression of CYR61 protein. We have
found that shCYR61 enhanced inhibition of proliferation and
motility/invasion induced by ZOL by S-phase accumulation. In
the same experimental conditions, CYR61 protein down-regula-
tion potentiated the inactivation of the ras-dependent prolifera-
tion pathway. Since CYR61 was reported to be involved in the
resistance to taxanes we have evaluated if ZOL could sensitize
PC3 cells to Docetaxel (DTX). We have found a sequence-depen-
dent synergism induced by the combination between ZOL and
G1–2 (%) G3 (%)
Gastrointestinal 75 0
Skin 29 11
Mucositis 17 23
Hypotirodism 23 0
Anemia 11 0
Leukopenia 11 0
Hearth 6 6
Fatigue 35 6
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DTX on PC3 cell growth inhibition and similar results were
recorded after transfection of PC3 cells with shCYR61. In conclu-
sion, it is possible to design new molecular rationale-based ther-
apeutic strategies in androgen-independent prostate cancer.
doi:10.1016/j.ejcsup.2008.06.047
DOCETAXEL AND ZOLEDRONIC ACID COMBINATION ADMINIS-
TERED IN TWO DIFFERENT SEQUENCES IN HORMONE
REFRACTORY PROSTATE CANCER PATIENTS: PHASE I CLINICAL
STUDY – ZANTE
G. Facchini a, M. Caraglia c, A. Morabito f, S.G. Bruni a, G. Nasti e, P.
Maiolino d, S. Striano b, A. Budillon c, A. Di Napoli a, M. Marra c, C.
Pisano a, S. Pignata a, F. Perrone f, R.V. Iaffaioli e. aMedical Oncology
Unit, Uro-Gynaecologic Department, Naples, Italy. bUrologic Unit, Uro-
Gynaecologic Department, Italy. cExperimental Pharmacology,
Italy. d Pharmacy Unit, National Cancer Institute, Naples, Italy. eColo-
Rectal Unit, National Cancer Institute, Naples, Italy. fClinical Trial Unit,
National Cancer Institute, Naples, Italy.
Background: Docetaxel (DTX) is effective in the treatment of
hormone-refractory prostate carcinoma patients (HRPC). In vitro
data suggest that zoledronic acid (ZOL) and DTX have a synergis-
tic effect on the growth inhibition of prostate cancer cells and
that such synergism is sequence-dependent. Therefore, prostate
cancer is a suitable target for a pharmacological combination
between DTX and ZOL. On the basis of these considerations, a
phase I trial on the combination of ZOL and DTX was designed
in the treatment of HRPC.
Materials: A dose-escalation of DTX was planned in combination
with a fixed dose of ZOL (2 mg), both administered every 14 days. The
following two different sequences of the two drugs were explored:
Sequence A: DTX at day 1 followed by ZOL at day 2. Sequence B:
ZOL at day 1 followed by DTX at day 2. The first dose level of DTX
was 30 mg/m2 with a planned dose escalation of 10 mg/m2 for each
level until 50 mg/m2. Serum cytokines and PBMC were also collected
prior and after the different treatments at each cycle.
Results: Up to now, we have enrolled 22 patients. Six patients at
third level (Sequence B) were required due a case of vascular tox-
icity of grade III (deep thrombo-phlebitis). A different pattern of
circulating sangiogenic factors (interleukin 8 and 12, VEGF, PDGF),
cytokines (TNF-a, IFN-c, interleukin 6 and 4) and gamma/delta T
lymphocyte subpopulation was recorded in the two different
sequences. The study is still ongoing and further results will be
presented at GOIM meeting.
doi:10.1016/j.ejcsup.2008.06.048
INTRAVESCICAL GEMCITABINE VERSUS MITOMYCIN FOR
RECURRENT SUPERFICIAL BLADDER TUMOURS (STAGES PTA
AND PT1): A RANDOMIZED PROSPECTIVE STUDY
Vincenzo Faiola a, Liliana Montella a, Raffaele Addeo a, Sergio
Bellini b, Antonio Miragliulo b, Gregorio Cennamo a, Rosario
Guarrasi a, Raffaele Gargiulo a, Michele Lanna b, Bruno Vincenzi d,
Michele Caraglia c, Salvatore Del Prete a. aU.O. Oncologia, Ospedale
SanGiovanni Di Dio ASLNA3, Frattamaggiore (NA), Italy. bU.O.
Urologia, Ospedale ‘‘Santa Maria Delle Grazie”, Casoria (NA),
Italy. cU.O. Frarmacologia Sperimentale, INT Pascale, Napoli,
Italy. dU.O. Oncologia, Campus Biomedico, Roma, Italy
Background: Approximately, 30–40% of patients with a superfi-
cial bladder cancer treated with Bacille Calmette-Guerin(BCG) or
epirubicin do not respond and other 35% of initial responders
have a relapse within 5 years. We compare the therapeutic effi-
cacy and toxicity of intravescical instillations of Gemcitabine
(GEM) with mitomycin C (MMC) in patients with a recurrent
superficial bladder cancer.
Methods: Patients with a history of a recurrent Ta-T1, G1-G2
bladder transitional cell carcinoma, previously treated were
enrolled in the study. The patients received a 6-week course of
GEM instillations or 4-week course of MMC. In both arms, for the
initial responders who remained free of recurrences, maintenance
therapy consisted of a 10 monthly treatment during the first year.
All patients were followed every 6 months by cystourethroscopy.
Results: A total of 120 patients were enrolled and randomly
assigned to either the MMC treatment arm or Gemcitabine treat-
ment arm. The remaining 109 patients (55 in MMC arm and 54 in
Gemcitabine arm) were evaluable. The median duration of follow-
up was (identical for both groups) 34 months.
Of the 54 patients in the Gemcitabine group 42(78%) remained
free of recurrence compared to 37 (67%) of the 55 patients treated
with MMC (p = 0.05). Among patients with recurrences, 10 in the
MMC arm and 6 in the Gemcitabine group had progressive disease
by stage: either local urothelial spread, or muscle infiltration, in 5
and 3, respectively. Local toxicity in both treatment groups was
acceptable. The incidence of. chemical cystitis in MMC arm was
statisticantly different from that in GEM group (p = 0,012).
Conclusions: Gemcitabine for its better clinical activity and
favourable toxicity profile than MMC, is a logical candidate for
intravescical therapy in refractory transitional cell patients. Final
results will be presented at 2008 ASCO Meeting.
doi:10.1016/j.ejcsup.2008.06.049
HIGH-DOSE CHEMOTHERAPY AS INITIAL SALVAGE TREATMENT
IN RELAPSED TESTICULAR CANCER PATIENTS
F. Morelli, A. Piano, A. Capotorto, L. Tozzi, S. Ronga, V.M. Valori, E.
Maiello. Oncology Unit, IRCCS Casa Sollievo della Sofferenza, San
Giovanni Rotondo (FG), Italy
Background: In the last few years, high dose chemotherapy
(HDCT) with haematopoietic stem cell transplantation (HSCT)
has been increasingly investigated as a therapeutic option for
early or late intensification in patients with poor prognosis germ
cell tumor (GCT) or in pats who relapse or who have a partial
response after a first line chemotherapy.
Methods: Eleven patients were treated with three cycles of VeIP
(ifosfamide 1200 mg/m2, mesna 1200 mg/m2, cisplatin 20 mg/m2,
days 1–5 and vinblastine 0.11 mg/kg, days 1–2) and one course
of HDCT: Carbo-PEC (carboplatin 400–550 mg/m2/day on day 1,
etoposide 450 mg/m2/day, cyclophosphamide 1600 mg/m2/day
and mesna 3600 mg/m2 on days 1–4) followed on day 7 by HSCT.
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